Health Economics›Gastric cancer›Metastatic or locally advanced disease first-line

Metastatic or locally advanced disease first-line

Gastric cancer · 55 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 23 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	—	~9.1 mo	~2	~R 573 911 PFS proxy · indirect	1
CapeOx, Pembrolizumab, Trastuzumab Variant #01	ERBB2	R 98 666	21d	10.0 mo	20.0 mo	3	R 272 566 PFS proxy	3
Cisplatin and Fluorouracil (CF), Pembrolizumab, Trastuzumab Variant #01	ERBB2	R 97 094	21d	10.0 mo	20.0 mo	3	R 267 850 PFS proxy	3
CapeOx and Pembrolizumab Variant #01	—	R 84 607	21d	—	12.9 mo	36	R 2 963 867 PFS proxy	1
Capecitabine and Cisplatin (CX) and Pembrolizumab Variant #01	—	R 83 467	21d	—	12.5 mo	2	R 166 934 PFS proxy	1
Cisplatin and Fluorouracil (CF) and Pembrolizumab Variant #01	—	R 83 223	21d	—	12.7 mo	35	R 2 876 965 PFS proxy	2
Capecitabine and Cisplatin (CX), Pertuzumab, Trastuzumab Variant #01	ERBB2	R 58 255	21d	—	18.1 mo	3	R 151 333 PFS proxy	1
Cisplatin and Fluorouracil (CF), Pertuzumab, Trastuzumab Variant #01	ERBB2	R 57 823	21d	—	18.1 mo	3	R 150 037 PFS proxy	1
mDCF and Bevacizumab Variant #01	—	R 22 225	14d	—	—	~2	~R 44 451 indirect	—
CapeOx and Trastuzumab Variant #01	ERBB2	R 16 679	21d	8.1 mo	16.8 mo	3	R 26 605 PFS proxy	2
Capecitabine and Cisplatin (CX) and Trastuzumab Variant #02	ERBB2	R 15 539	21d	—	13.8 mo	3	R 23 185 PFS proxy	2
Cisplatin and Fluorouracil (CF) and Trastuzumab Variant #01	ERBB2	R 15 107	21d	8.1 mo	14.2 mo	3	R 21 889 PFS proxy	4
CLF Variant #03	—	R 13 479	14d	3.9 mo	—	2	R 22 266 PFS proxy	—
Fluorouracil, Folinic acid, Mitomycin Variant #01	—	R 12 524	56d	—	—	~2	~R 25 048 indirect	—
mFOLFOX6 and Zolbetuximab Variant #01 Partial	—	R 8 083	42d	10.6 mo	18.2 mo	5	R 36 621 PFS proxy	2
OLF Variant #01	—	R 5 085	56d	5.8 mo	—	2	R 10 171 PFS proxy	—
EOX Variant #01	—	R 3 772	21d	5.5 mo	11.3 mo	9	R 31 213 PFS proxy	3
FULV Variant #29	—	R 3 601	14d	—	7.5 mo	2	R 7 201 PFS proxy	1
EOF Variant #01	—	R 3 582	21d	—	~48.0 mo	~8	~R 28 660 PFS proxy · indirect	1
DCF Variant #01	—	R 3 508	21d	—	9.2 mo	2	R 7 015 PFS proxy	1
Cisplatin and Docetaxel (DC) Variant #05	—	R 3 185	21d	~24.0 mo	—	~3	~R 9 556 PFS proxy · indirect	1
mFOLFOX6 and Nivolumab Variant #01 Partial	—	R 3 180	14d	—	14.4 mo	2	R 6 359 PFS proxy	1
FAM Variant #01	—	R 2 760	56d	—	—	~2	~R 5 520 indirect	—
Irinotecan monotherapy Variant #01	—	R 2 716	42d	~2.3 mo	~8.4 mo	~11	~R 29 874 PFS proxy · indirect	9
ECX Variant #01	—	R 2 632	21d	—	10.7 mo	3	R 7 896 PFS proxy	1
CapeOx and Nivolumab Variant #01 Partial	—	R 2 620	21d	10.7 mo	17.5 mo	2	R 5 240 PFS proxy	5
CapeOx Variant #01	ERBB2	R 2 620	21d	6.5 mo	12.2 mo	2	R 5 240 PFS proxy	15
CapeOx Variant #01	—	R 2 620	21d	6.5 mo	12.2 mo	2	R 5 240 PFS proxy	15
CapeOx and Tislelizumab Variant #01 Partial	—	R 2 620	21d	—	15.0 mo	2	R 5 240 PFS proxy	1
CapeOx and Zolbetuximab Variant #01 Partial	—	R 2 620	21d	8.2 mo	14.4 mo	9	R 21 997 PFS proxy	2
mFOLFOX6 Variant #02	—	R 2 617	14d	7.6 mo	12.2 mo	2	R 5 233 PFS proxy	4
Docetaxel and S-1 Variant #01 Partial	—	R 2 597	21d	—	12.5 mo	8	R 20 775 PFS proxy	1
ECF Variant #01	—	R 2 442	21d	—	9.2 mo	6	R 14 655 PFS proxy	—
FOLFIRI Variant #05	—	R 2 314	14d	~8.2 mo	~16.1 mo	~5	~R 11 572 PFS proxy · indirect	22
mFOLFOX6 (L-Leucovorin) Variant #01 Partial	—	R 2 054	14d	—	11.8 mo	2	R 4 107 PFS proxy	—
mDCF Variant #01	—	R 1 957	14d	—	10.2 mo	8	R 15 652 PFS proxy	1
FEMTX Variant #01	—	R 1 833	28d	—	—	~2	~R 3 667 indirect	—
Cisplatin and Fluorouracil (CF) Variant #01	ERBB2	R 1 783	28d	5.0 mo	11.1 mo	3	R 5 350 PFS proxy	7
Cisplatin and Fluorouracil (CF) Variant #01	—	R 1 783	28d	5.0 mo	11.1 mo	3	R 5 350 PFS proxy	7
Capecitabine and Cisplatin (CX) Variant #01	—	R 1 480	21d	5.4 mo	10.6 mo	2	R 2 960 PFS proxy	8
Capecitabine and Cisplatin (CX) Variant #01	ERBB2	R 1 480	21d	5.4 mo	10.6 mo	2	R 2 960 PFS proxy	8
SOX Variant #01 Partial	—	R 1 265	21d	5.6 mo	—	2	R 2 530 PFS proxy	2
Paclitaxel and S-1 Variant #01 Partial	—	R 1 224	35d	—	17.7 mo	2	R 2 448 PFS proxy	1
UFTM Variant #01 Partial	—	R 1 135	7d	—	—	~2	~R 2 269 indirect	—
Cisplatin and Fluorouracil (CF) and Tislelizumab Variant #01 Partial	—	R 1 048	21d	—	15.0 mo	2	R 2 096 PFS proxy	1
Capecitabine monotherapy Variant #01	—	R 1 039	21d	—	6.9 mo	2	R 2 077 PFS proxy	2
Carboplatin and Paclitaxel (CP) Variant #02	—	R 1 025	21d	~7.4 mo	~27.5 mo	~18	~R 18 445 PFS proxy · indirect	3
Fluorouracil and Heptaplatin (FH) Variant #01 Partial	—	R 809	28d	—	7.3 mo	2	R 1 618 PFS proxy	—
Fluorouracil and RT Variant #01	—	R 809	42d	—	~13.6 mo	~1	~R 809 PFS proxy · indirect	5
FAMTX Variant #01	—	R 763	28d	—	—	~2	~R 1 527 indirect	—
Fluorouracil monotherapy Variant #01	—	R 647	28d	—	10.8 mo	2	R 1 294 PFS proxy	2
Cisplatin and S-1 Variant #01 Partial	—	R 441	28d	5.5 mo	14.1 mo	8	R 3 530 PFS proxy	10
FULV (L-Leucovorin) Variant #06 Partial	—	R 61	14d	—	6.1 mo	30	R 1 820 PFS proxy	1
Best supportive care Partial	—	—	—	—	~3.7 mo	—	—	4
S-1 monotherapy Variant #01 Partial	—	—	21d	—	10.9 mo	2	—	6

55 of 55 regimens shown